Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas
暂无分享,去创建一个
H Evans | E S Newlands | P. Price | J. Matthews | E. Newlands | C. Brock | H. Young | H Young | P M Price | C S Brock | S M O'Reilly | J Matthews | S Osman | S. O'Reilly | S. Osman | H. Evans | S. O’Reilly | Cathryn S. Brock | Patricia Price | Safiye Osman | Susan M. O'Reilly
[1] K. Hamacher,et al. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] R L Wahl,et al. An Immunohistochemical Study , 2006 .
[3] R. P. Maguire,et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[4] J. Dobkin,et al. Glucose uptake by gliomas after treatment. A positron emission tomographic study. , 1989, Archives of neurology.
[5] C. Kennard,et al. Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. , 1993, European journal of cancer.
[6] M. Bennett,et al. Isoenzymes of hexokinase in the developing, normal and neoplastic human brain. , 1978, European journal of cancer.
[7] R L Wahl,et al. Intratumoral distribution of tritiated-FDG in breast carcinoma: correlation between Glut-1 expression and FDG uptake. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[8] U Ruotsalainen,et al. Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] P M Bloomfield,et al. The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. , 1991, Medical progress through technology.
[10] J. Mazziotta,et al. Rapid Automated Algorithm for Aligning and Reslicing PET Images , 1992, Journal of computer assisted tomography.
[11] T. Fukumura,et al. Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[12] A. Dwyer,et al. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. , 1995, Journal of neurosurgery.
[13] R. G. Manning,et al. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. , 1982, Radiology.
[14] F. Berthold,et al. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment , 1993, Cancer.
[15] Heikki Joensuu,et al. Florodeoxyglucose imaging: A method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors , 1988 .
[16] M. Rathbone,et al. Postoperative contrast enhancement in patients with brain tumor , 1985, Annals of neurology.
[17] Peter Molnar,et al. Application of Quantitative Autoradiographic Measurements in Experimental Brain Tumor Models , 1981 .
[18] Y Yonekura,et al. Effects of hyperglycemia on FDG uptake in human brain and glioma. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[19] R L Wahl,et al. Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] F. Fazio,et al. Errors Introduced by Tissue Heterogeneity in Estimation of Local Cerebral Glucose Utilization with Current Kinetic Models of the [18F]Fluorodeoxyglucose Method , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[21] E. Hoffman,et al. TOMOGRAPHIC MEASUREMENT OF LOCAL CEREBRAL GLUCOSE METABOLIC RATE IN HUMANS WITH (F‐18)2‐FLUORO-2‐DEOXY-D‐GLUCOSE: VALIDATION OF METHOD , 1980, Annals of neurology.
[22] T. Jones,et al. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group. , 1995, European journal of cancer.
[23] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] P. Isaacson,et al. Immunoproliferative small-intestinal disease. An immunohistochemical study. , 1989, The American journal of surgical pathology.
[25] N. Bleehen,et al. A randomized study of CCNU with and without benznidazole in the treatment of recurrent grades 3 and 4 astrocytoma. Report to the Medical Research Council by the Brain Tumor Working Party. , 1989, International journal of radiation oncology, biology, physics.
[26] D. Altman,et al. STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.
[27] L M Hamberg,et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[28] Abass Alavi,et al. Positron emission tomography in patients with glioma a predictor of prognosis , 1988, Cancer.
[29] G A Ojemann,et al. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[30] K Wienhard,et al. Validity of PET studies in brain tumors. , 1990, Cerebrovascular and brain metabolism reviews.
[31] P. Gutin,et al. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. , 1988, Journal of neurosurgery.
[32] L. Weisberg. Postoperative contrast enhancement in patients with brain tumor , 1986, Annals of neurology.
[33] D J Brooks,et al. Measurement of Glucose Utilisation with [18F]2-Fluoro-2-Deoxy-D-Glucose: A Comparison of Different Analytical Methods , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[34] H. Minn,et al. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] C. D. Arnett,et al. Glucose Metabolic Rate Kinetic Model Parameter Determination in Humans: The Lumped Constants and Rate Constants for [18F]Fluorodeoxyglucose and [11C]Deoxyglucose , 1985, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[36] E. Newlands,et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). , 1992, British Journal of Cancer.
[37] H. Minn,et al. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. , 1988, Cancer.
[38] R A Brooks,et al. Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography , 1982, Neurology.
[39] K Herholz,et al. Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. , 1993, Journal of neurosurgery.
[40] M. Reivich,et al. THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.
[41] J. Cairncross,et al. Steroid‐induced CT changes in patients with recurrent malignant glioma , 1988, Neurology.
[42] J. Bergh,et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] E. Hoffman,et al. Noninvasive determination of local cerebral metabolic rate of glucose in man. , 1980, The American journal of physiology.
[44] J. Itami,et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[45] N. Alpert,et al. FDG-PET in oncology: there's more to it than looking at pictures. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[46] A. Luxen,et al. Acute effect of carmustine on glucose metabolism in brain and glioblastoma , 1994, Cancer.